How should eplerenone be used in adults with heart failure with reduced ejection fraction, including dosing, monitoring, and contraindications?

Eplerenone in Heart Failure with Reduced Ejection Fraction

Eplerenone should be initiated at 25 mg once daily in patients with HFrEF who have LVEF ≤35-40%, NYHA class II-IV symptoms, are already on optimal doses of ACE inhibitor (or ARB) and beta-blocker, have adequate renal function (eGFR >30 mL/min/1.73 m²), and serum potassium <5.0 mEq/L. 1, 2

Patient Selection Criteria

Eplerenone is indicated for patients meeting ALL of the following:

• LVEF ≤35-40% (post-MI patients can have LVEF up to 40%) 3, 4
• NYHA class II-IV symptoms (moderate to severe heart failure) 3, 1
• Already receiving optimal therapy with ACE inhibitor or ARB AND beta-blocker 3
• Adequate renal function: eGFR >30 mL/min/1.73 m² 1, 2
• Normal potassium: <5.0 mEq/L at initiation 5, 1, 2

The evidence supporting eplerenone comes primarily from the EPHESUS trial, which demonstrated a 15% reduction in all-cause mortality in post-MI patients with HFrEF 3. This mortality benefit is substantial and positions mineralocorticoid receptor antagonists as Class I, Level A therapy in current guidelines 1, 2.

Absolute Contraindications

Do NOT use eplerenone if:

• Serum potassium ≥5.0 mEq/L at baseline 5, 1
• eGFR ≤30 mL/min/1.73 m² 1, 2
• Creatinine >2.5 mg/dL in men or >2.0 mg/dL in women 5, 6
• Patient is taking BOTH an ACE inhibitor AND an ARB (triple RAAS blockade is harmful) 3, 7

Dosing Protocol

Initiation

1. Starting dose: 25 mg once daily 3, 5, 4
2. For patients with eGFR 31-49 mL/min/1.73 m², consider starting at 25 mg every other day 5, 2
3. Check potassium and renal function at 1 week and 4 weeks after initiation 3

Titration

After 4-8 weeks, if potassium remains <5.0 mEq/L and renal function is stable:

• Increase to target dose of 50 mg once daily 3, 4
• Recheck potassium and creatinine at 1 and 4 weeks after dose increase 3

Maintenance Monitoring

Once at maintenance dose, monitor potassium and renal function at:

• 1,2,3, and 6 months, then every 6 months thereafter 3
• More frequently if clinical instability, diuretic changes, or other RAAS inhibitor adjustments 2

Managing Adverse Effects

Hyperkalemia Management Algorithm

Potassium 5.0-5.4 mEq/L:

• Continue current dose, monitor closely 3

Potassium 5.5-5.9 mEq/L:

• Reduce dose by 50% (e.g., 50 mg daily → 25 mg daily, or 25 mg daily → 25 mg every other day) 3, 4
• Recheck potassium within 3-7 days

Potassium ≥6.0 mEq/L:

• STOP eplerenone immediately 3, 4
• Monitor potassium closely and treat hyperkalemia
• May restart at 25 mg every other day once potassium <5.5 mEq/L 4

If potassium cannot be maintained <5.5 mEq/L, discontinue permanently to avoid life-threatening hyperkalemia 2

Worsening Renal Function

Creatinine rises to 220-310 µmol/L (2.5-3.5 mg/dL):

• Reduce dose by 50% (e.g., to 25 mg every other day) 3
• Monitor closely

Creatinine >310 µmol/L (>3.5 mg/dL):

• STOP eplerenone immediately 3
• Evaluate for specific treatment of renal dysfunction

Critical Clinical Pitfalls

1. Real-world hyperkalemia risk is HIGHER than in trials: The EPHESUS and EMPHASIS-HF trials showed <1% clinically significant hyperkalemia 2, but observational data demonstrate higher rates in routine practice, especially in elderly patients with multiple comorbidities 3, 2. This mandates vigilant monitoring.

2. Avoid triple RAAS blockade: Do not combine eplerenone with both an ACE inhibitor AND an ARB—this increases cardiovascular and renal risk 8, 7. Use eplerenone with EITHER an ACE inhibitor OR an ARB, not both.

3. Discontinue potassium supplements: When starting eplerenone, stop potassium supplementation and counsel patients to avoid high-potassium foods and NSAIDs 5.

4. Temporary holds during acute illness: Consider holding eplerenone during episodes of diarrhea, dehydration, or when loop diuretics are interrupted, as these increase hyperkalemia risk 2.

Eplerenone vs. Spironolactone

Eplerenone causes less gynecomastia and breast tenderness than spironolactone (infrequent vs. 10% in RALES) 3. The primary indication for choosing eplerenone over spironolactone is in men experiencing breast-related side effects from spironolactone 3. Both agents have equivalent aldosterone-blocking efficacy and mortality benefits 3.

Economic Value

Eplerenone therapy provides high economic value in HFrEF patients, with cost per quality-adjusted life year under $1,000 using generic pricing 2. The mortality benefit (15% relative risk reduction in EPHESUS) translates to meaningful absolute benefit in this high-risk population 3.